Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Booking Holdings Inc (BKNG) vs Eli Lilly And Co (LLY) Price & Performance

Booking Holdings IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Booking Holdings Inc vs Eli Lilly And Co — how do they compare? Booking Holdings Inc trades at $212.26 (market cap $159.95B), while Eli Lilly And Co trades at $1,221.01 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 6.8× Booking Holdings Inc's market cap, and Booking Holdings Inc pays the higher dividend (0.79%). Which is the better fit depends on your goals.

BKNGLLY
Market Cap
$159.95B$1.08T
Sector
Consumer CyclicalHealth
52-Week High
$228.83$1.24K
52-Week Low
$154.13$639.43
Enterprise Value
$163.43B$1.13T
Dividend Yield
0.79%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Booking Holdings Inc

BKNG trades at $212.26, down 0.29% on the day, with a bullish technical signal from moving averages and strong support at $212. The company reported Q2 2026 EPS of $2.54, beating estimates, and revenue growth remains robust, though net income margin dipped to 20.07% in 2025. Analyst consensus is strongly bullish with a $239.31 price target, and recent news highlights resilient travel demand and AI integration efforts.

The outlook for BKNG is positive, driven by earnings beats and solid cash flow, but risks include geopolitical volatility and high debt levels. Upside potential exists if travel demand sustains and margins improve, yet investors face headwinds from competitive pressures and economic sensitivity.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Booking Holdings Inc

Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.

Read more on BKNG

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY